Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in alzheimer’s disease

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 8, 2014, Pages 1315-1324

  Ahmad, Mohammad Z ^a   Ahmad, Javed ^b   Amin, Saima ^b   Rahman, Mahfoozur ^b   Anwar, Mohammad ^b   Mallick, Neha ^b   Ahmad, Farhan J ^b   Rahman, Ziyaur ^c   Kamal, Mohammad A ^d   Akhter, Sohail ^e  

^a NAJRAN UNIVERSITY   (Saudi Arabia)

^b HAMDARD UNIVERSITY   (India)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer s disease; Blood brain barrier; Brain targeting; Cholinesterase inhibitors; Curcumin; Donepezil; Galantamine; Nanomedicines; Nanoparticles; Resveratrol; Rivastigmine; Tacrine; Thymoquinone

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; CHOLINESTERASE INHIBITOR LOADED NANOPARTICLE; CLIOQUINOL; CURCUMIN; DONEPEZIL; FLAVONOID; GALANTAMINE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PHYSOSTIGMINE; POLYGLACTIN; POLYLACTIC ACID; POLYPHENOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL; RIVASTIGMINE; TACRINE; THYMOQUINONE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; NANOMEDICINE; NONHUMAN; OXIDATIVE STRESS; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CHOLINESTERASE INHIBITORS; HUMANS; NANOMEDICINE;

EID: 84925782924     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666141023100618     Document Type: Article

References (110)

1. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis 2013; 33 Suppl 1: S405-16.
2. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology 2014; 76 Pt A: 27-50.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3(3): 186-91.
4. Rasool M, Malik A, Qazi A, et al. Current View from Alzheimer Disease to Type 2 Diabetes Mellitus. CNS Neurol Disord Drug Targets 2014; 13(3): 533-42.
5. Rajadhyaksha M, Boyden T, Liras J, El-Kattan A, Brodfuehrer J. Current advances in delivery of biotherapeutics across the bloodbrain barrier. Curr Drug Discov Technol 2011; 8(2): 87-101.
6. Shaikh S, Ahmad SS, Ansari MA, et al. Prediction of Comparative Inhibition Efficiencies for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study. CNS Neurol Disord Drug Targets 2013; 13(3): 452-9.
7. Reale MA, Di Nicola M, Velluto L, et al. Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce amyloid-β Ex Vivo Activation of Peripheral Chemo-Cytokines from Alzheimer's disease Subjects: Exploring the Cholinergic Anti-Inflammatory Pathway. Curr Alzheimer Res 2014; 11(6): 608-22.
8. Rylett RJ, Ball MJ, Colhoun EH. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res 1983; 289(1-2): 169-75.
9. Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B. Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 1986; 67(3-4): 275-85.
10. Mirza Z, Ali A, Ashraf GM, et al. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13(2): 213-25.
11. Alam A, Shaikh S, Ahmad SS, et al. Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach. CNS Neurol Disord Drug Targets 2013; 13(3): 487-90.
12. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66(2): 137-47.
13. Sahni JK, Doggui S, Ali J, et al. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 2011; 152(2): 208-31.
14. Anand P, Singh B, Singh N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg Med Chem 2012; 20(3): 1175-80.
15. Verma A1, Siddiqui S, Ahmad SS, et al. Current Acetylcholinesterase-Inhibitors: A Neuroinformatics Perspective. CNS Neurol Disord Drug Targets 2013; 13(3): 391-401.
16. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7(6): 293-3.
17. Sheikh IA, Ali R, Dar TA, Kamal MA. An overview on potential neuroprotective compounds for management of Alzheimer's disease. CNS Neurol Disord Drug Targets 2012; 11: 1006-11.
18. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann NY Acad Sci 2000; 920: 321-7.
19. Seitz DP, Gruneir A, Conn DK, Rochon PA. Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey. J Am Geriatr Soc 2009; 57(12): 2269-74.
20. Hughes A, Musher J, Thomas SK, et al. Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors. Consult Pharm 2004; 19(8): 713-20.
21. Schilstrom B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007; 32(1): 43-53.
22. Aricept. Eisai Inc. and Pfizer Inc. 2014; Available from: http: //www.aricept.com
23. Herrmann N, Chau SA, Kircanski I, Lanctôt KL. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011; 71(15): 2031-65.
24. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013; 5(1): 6.
25. Eisai Limited. Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease (NCT00478205). Eisai Inc.: 2014; NCT00478205.
26. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer’s disease: epidemiology and management. Drugs Aging 2001; 18: 853-62.
27. Exelon. 2013; Avialble from: http:/www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf
28. Emre M, Bernabei R, Blesa R, et al. Drug profile: transdermal Rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther 2010; 16: 246-53.
29. Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 2011; 8(5): 581-603.
30. Sadowsky C, Perez JA, Bouchard RW, Goodman I, Tekin S. Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010; 16(1): 51-60.
31. Yang LPH, Keating GM. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s type. CNS Drugs 2007; 21: 957-65.
32. Winblad B, Cummings J, Andreasen N, et al. A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease -- Rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
33. Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of Rivastigmine transdermal patch compared with Rivastigmine capsules in patients switched from Donepezil: data from three clinical trials. Int J Clin Pract 2010; 64: 188-93.
34. Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease. Clin Interv Aging 2010; 5: 1-6.
35. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 2011; 116(1): 6-17.
36. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002; (3): CD001747.
37. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004; 52(7): 1070-6.
38. Benech H, Vincenti M, Fouchart F, et al. Development and in vivo assessment of a transdermal system for physostigmine. Methods Find Exp Clin Pharmacol 1998; 20(6): 489-98.
39. Walter K, Müller M, Barkworth MF, Nieciecki AV, Stanislaus F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol 1995; 39(1): 59-63.
40. Moller H-J, Hampel H, Hegerl U, Schmitt W, Walter K. Doubleblind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Pharmacopsychiatry 1999; 32(3): 99-106.
41. Greig NH, Ruckle J, Comer P, et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2005; 2(4): 483-92.
42. Utsuki T, Uchimura N, Irikura M, et al. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. J Pharmacol Exp Ther 2007; 321(1): 353-61.
43. Telting-Diaz M, Lunte CE. Distribution of Tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharm Res 1993; 10: 44-8.
44. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of Tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995; 14: 75-83.
45. Ganguli M, Chandra V, Kamboh MI, et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross- National Dementia Study. Arch Neurol 2000; 57(6): 824-30.
46. Changwong N, Sabphon C, Ingkaninan K, Sawasdee P. Acetyl- and butyryl-cholinesterase inhibitory activities of mansorins and mansonones. Phytother Res 2012; 26(3): 392-6.
47. Piazzi L, Cavalli A, Colizzi F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti- Alzheimer compounds. Bioorg Med Chem Lett 2008; 18(1): 423-6.
48. Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetyl cholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease. Pharmacol Biochem Behav 2009; 91: 554-59.
49. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Epigallocatechin-3-gallate and curcumin suppress amyloid betainduced beta-site APP cleaving enzyme-1 upregulation. Neuroreport 2008; 19: 1329-33.
50. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284): 99-02.
51. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
52. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22(6): 993-1005.
53. Begum AN, Jones MR, Lim GP, et al. Curcumin structurefunction, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008; 326(1): 196-208.
54. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 2004; 6: 367-77.
55. Kim YA, Lim SY, Rhee SH, et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in betaamyloid- treated C6 glioma cells. Int J Mol Med 2006; 17(6): 1069-75.
56. Anekonda TS. Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 2006: 316-26.
57. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280(45): 37377-82.
58. Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxiderelated toxicity in cultured hippocampal neurons. Br J Pharmacol 2000; 131(4): 711-20.
59. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002; 71(21): 2489-98.
60. Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloidinduced oxidative PC12 cell death. Free Radic Biol Med 2003; 34: 1100-10.
61. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334-50.
62. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nurt Rev 2004; 62: 204-11.
63. Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloidinduced toxicity. Eur J Neurosci 2006; 23: 55-64.
64. Choi YT, Jung CH, Lee SR, et al. The green tea polyphenol (-)- epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001; 70(5): 603-14.
65. Iqbal A1, Ahmad I, Khalid MH, et al. Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013; 31: 256-84.
66. Ono K, Yoshiike Y, Takashima A, et al. Potent antiamyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-81.
67. Dube KNA, Nicolazzo JA, Larson I. Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution. Food Chem 2010; 122: 662-7.
68. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9(9): 3312-9.
69. Renouf M, Guy P, Marmet C, et al. Plasma appearance and correlation between coffee and green tea metabolites in human subjects. Br J Nutr 2010; 104(11): 1635-40.
70. Norsharina I, Maznah I, Iqbal S, Latiff, LA. Anti-aggregation effects of thymoquinone against Alzheimer’s β -amyloid in vitro. Med Plants Res 2013; 7(31): 2280-8.
71. Alhebshi AH, Gotoh M, Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid β -induced neurotoxicity. Biochem Biophys Res Commun 2013; 433(4): 362-7.
72. Khan A, Vaibhav K, Javed H, et al. Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 2012; 369(1- 2): 55-65.
73. Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 1997; 277(10): 776.
74. Kamal MA, Greig NH, Alhomida AS, Al-Jafari AA. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. Biochem Pharmacol 2000; 60(4): 561-70.
75. Bai DL, Tang XC, He XC. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 2000; 7(3): 355-74.
76. Wang YE, Yue DX, Tang XC. Anti-cholinesterase activity of huperzine A. Zhongguo Yao Li Xue Bao 1986; 7(2): 110-3.
77. Rip J, Schenk GJ, de Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv 2009; 6: 227-37.
78. Alam Q, Haque A, Alam MZ, et al. Nanotechnological Approach in Management of Alzheimer's Diseases and Type- 2 Diabetes. CNS Neurol Disord Drug Targets 2014; 13(3): 478-86.
79. Stewart PA. Endothelial vesicles in the blood-brain barrier: are they related to permeability? Cell Mol Neurobiol 2000; 20: 149-63.
80. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cel Mol Neurobiol 2005; 25: 5-23.
81. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 2013; 41(1): 33-9.
82. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
83. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006; 1: 223-36.
84. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 7: 41-53.
85. Ramsauer M, Kunz J, Krause D, Dermietzel R. Regulation of a blood-brain barrier-specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) under cell culture conditions, J Cereb Blood Flow Metab 1998; 18: 1270-81.
86. Kuwahara H, Nishida Y, Yokota T. Blood-brain barrier and Alzheimer's disease. Brain Nerve 2013; 65(2): 145-51.
87. Rapoport SI. Modulation of blood-brain barrier permeability. J Drug Target 1996; 3: 417-25.
88. Sharma HS, Castellani RJ, Smith MA, Sharma A. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 2012; 102: 47-90.
89. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Rel 2005; 108(2-3): 193-214.
90. Wilson B, Samanta MK, Santhi K, et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(nbutylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008; 70(1): 75-84.
91. Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2010; 6(1): 144-52.
92. Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25(5): 408-22.
93. Lilienfeld. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Re 2002; 8(2): 159-76.
94. Fazil M, Shadab M, Baboota S, Sahni JK, Ali J. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future. J Drug Target 2012; 20(2): 97-113.
95. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010; 76(2): 189-99.
96. Fazil M, Md S, Haque S, et al. Development and evaluation of Rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012; 47(1): 6-15.
97. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci 2009; 37(3-4): 395-4.
98. Sun, M, Gao Y, Guo C, et al. Enhancement of transport of curcumin to brain in mice by poly (n-butylcyanoacrylate) nanoparticle. J Nanopart Res 2010; 12(8): 3111-22.
99. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly (butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm 2010; 7(3): 815-25.
100. Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V. Apolipoprotein E LDL receptor-binding domain-containing highdensity lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta 2011; 1808: 352-9.
101. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 2011; 23(1): 61-77.
102. Cheng KK, Yeung CF, Ho SW, et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J 2013; 15(2): 324-36.
103. Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 2011; 32(6): 1635-45.
104. Lazar AN, Mourtas S, Youssef I, et al. Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine 2013; 9(5): 712-21.
105. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One 2012; 7(3): e32616.
106. Doggui S, Sahni JK, Arseneault M, Dao L, Ramassamy C. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimers Dis 2012; 30(2): 377-92.
107. Kulkarni PV, Roney CA, Antich PP, et al. Quinoline-nbutylcyanoacrylate- based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2: 35-47.
108. Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007; 16(12): 1921-31.
109. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224(3): 274-83.
110. Lu X, Ji C, Xu H, et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm 2009; 375(1-2): 89-96.